Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia 10Burkitt Lymphoma 7Leukemia, Biphenotypic, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 2Recurrence 1Lymphoma, T-Cell 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Down Syndrome 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Thioguanine 2Cytarabine 2pegaspargase 1merphos 1dexamethasone acetate 1dexamethasone 21-phosphate 1azathiopurine 1auricularum 1asparaginase erwinia chrysanthemi recombinant 1Vincristine 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Leyk 1Leucovorin 1Etoposide 1Doxorubicin 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Calcium Dobesilate 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Down Syndrome × pegaspargase × Clear all
NCT01190930 2026-05-22

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡